The
biopharmaceutical company
Genmab A/S has reported various key business developments. This includes a
DKK 615 Million Share Buy-back Program completion, the formation of the board of directors and the announcement of restricted stock units and warrants to its employees. Notably, the biotech firm
maintains a Buy rating as per H.C. Wainwright and has received an overweight rating from Wells Fargo. The company’s progress reflects in the
rising relative strength of its stocks and its significant stock holdings worth $335.96 Million. Genmab’s
expansion efforts include the opening of a new U.S. Hub to bolster global growth. The company’s notable partnerships include an
AI partnership with Anthropic. Amidst these advancements, Genmab reported a
missed endpoint in its Phase 3 epcoritamab trial and the discontinuation of acasunlimab development, causing stock dips. However, its overall
profitability remains high, driven by robust demand for its leading product, Darzalex, delivering a 19% revenue growth amounting to $3.7B in 2025.
Genmab Stocks News Analytics from Mon, 11 Aug 2025 07:00:00 GMT to Fri, 20 Mar 2026 11:05:23 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -2
